- Home
- AMSF vs FDMT Comparison
AMSF vs FDMT Comparison
Compare AMSF & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMSF | FDMT |
|---|---|---|
| Founded | 1985 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 584.3M | 479.9M |
| IPO Year | 1996 | 2019 |
Fundamental Metrics
Financial Performance| Metric | AMSF | FDMT |
|---|---|---|
| Price | $31.40 | $8.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $46.33 | $31.71 |
| AVG Volume (30 Days) | 208.9K | ★ 578.4K |
| Earning Date | 04-22-2026 | 05-08-2026 |
| Dividend Yield | ★ 8.61% | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $317,252,000.00 | $85,209,000.00 |
| Revenue This Year | $8.45 | N/A |
| Revenue Next Year | $6.03 | $70.28 |
| P/E Ratio | $72.95 | ★ N/A |
| Revenue Growth | 2.66 | ★ 230194.60 |
| 52 Week Low | $29.42 | $3.37 |
| 52 Week High | $47.86 | $12.34 |
Technical Indicators
Market Signals| Indicator | AMSF | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 51.46 | 37.71 |
| Support Level | $29.44 | $6.22 |
| Resistance Level | $34.15 | $8.80 |
| Average True Range (ATR) | 0.70 | 0.65 |
| MACD | 0.24 | -0.17 |
| Stochastic Oscillator | 85.56 | 10.83 |
Price Performance
Historical ComparisonAbout AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums. The Company operates as a single reportable segment, Insurance Operations.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).